Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
April 03, 2024 08:40 ET
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
April 01, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Provides Third Quarter 2023 Financial Results
November 08, 2023 16:05 ET
|
Surrozen, Inc.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...
Surrozen Provides Second Quarter 2023 Financial Results
August 09, 2023 16:05 ET
|
Surrozen, Inc.
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...
Michael White, Ph.D. joins Samumed as Chief Scientific Officer
June 01, 2020 11:00 ET
|
Samumed, LLC.
SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will...
Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
May 22, 2020 09:00 ET
|
Samumed, LLC.
SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...